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Dear Editor,
In December 2019 in the Hubei province of China began a pandemic
outbreak sustained by a novel coronavirus named Severe Acute
Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The syndrome
sustained by this virus has been named COronaVirus Disease 2019
(COVID-19) and respiratory illness is the dominant clinical manifesta-
tion [1]. From its onset, the virus rapidly spread in the world, leading
the World Health Organization officially to declare a pandemic state on
March 11, 2020, resulting in 1.812.734 confirmed cases of COVID-19,
with more than 113.675 patients who died [World Health Organization.
Coronavirus disease 2019 (COVID-19) Situation reports. https://www.
who.int/emergencies/diseases/novel-coronavirus-2019/situation-
reports, last access 14, April 2020].
To date, COVID-19 seems to have a lower mortality compared to the
most important other human coronavirus syndromes (SARS-1 and
MERS), but a dramatically greater spread [1]. This diffusion is favoured
by infective carriers in which the virus produces no or mild flu-like
syndrome during the whole duration of the disease after an incubation
time (of 1–14 days). However, moderate-to-severe COVID-19 patients
are very numerous and raise management concerns due to the satura-
tion of Intensive Care Units (ICU).
Great importance in the mortality associated with coronaviruses
infection has been given to the concomitant comorbidities of the pa-
tients. For COVID-19, a close correlation has been found with diabetes,
hypertension, cardiovascular disease, whereas chronic obstructive lung
disease, chronic liver disease and malignancies were reported in about
1–7% of patients who died [2].
Immunocompromised patients are rarely reported in SARS-1 and
MERS cohorts [3–5] and mainly referred to patients with active cancer
under chemotherapy (about 5–6% of patients). Particularly, the pre-
valence of coronaviruses infection in patients with autoimmune dis-
eases is lacking in previous literature. This issue raises several concerns
regarding the utility to continue immunosuppressive agents in this co-
hort of patients during outbreak [6,7]. Recently, Monti et al. [8] re-
ported that patients with rheumatoid arthritis treated with biological
DMARDs or targeted synthetic DMARDs did not seem to be at increased
risk of life-threatening complications from SARS-CoV-2 compared with
general population. Similarly, recent publications reported no cases of
complicated SARS-CoV-2 related pneumonia in inflammatory bowel
diseases, even in those patients under immunosuppressive treatment
[9,10].
Whilst these figures are reassuring, the scenario could be quite
different with regard to patients suffering from systemic sclerosis (SSc).
SSc is a rare multifaceted autoimmune disorder characterized by in-
flammatory, vascular, and fibrotic processes resulting in skin fibrosis
and multiple organ manifestations [11]. Lung involvement, i.e., inter-
stitial lung disease (ILD) and pulmonary hypertension, is a common
manifestation and develops in up to 75% of patients with SSc overall.
To date, ILD represents the main cause of death in these patients [12].
Although at the moment the treatment of SSc is not well established,
currently therapy of SSc patients focuses on immunosuppressant agents,
particularly cyclophosphamide and mycophenolate mofetil. Further-
more some patients undergo conditioning immunosuppressive therapy
before autologous stem cell transplantation (ASCT) [12,13]. More re-
cently, consistent data have been published on the potential effective-
ness of rituximab and anti-interleukin (IL) 6 receptor blocker tocili-
zumab in the improvement/stabilization of SSc ILD [13]. Since the lung
disease and immunosuppression are WHO-defined risk factors for a
more severe course of COVID-19, SSc patients could represent a pecu-
liar subgroup of patients at increased risk of respiratory or life-threa-
tening complications from SARS-CoV-2 compared with other auto-
immune diseases. Very recently, Mihai et al. reported the observation of
a SSc patient who developed a mild form of COVID-19, even in the
presence of ILD treated with tocilizumab and type 2 diabetes mellitus
[14].
More severe forms of COVID-19 are characterized by acute systemic
inflammatory response and cytokine storm, which can result in injury
to multiple organs. Different studies have shown that high circulatory
levels of pro-inflammatory cytokines correlate with disease severity and
poor prognosis during SARS-CoV2 infection [15]. Inflammation occurs
to restore the homeostasis after viral infection and could be harmful if
excessive. In this respect, Xu et al. [16] found an overactivation of T
cells, manifested by increase of Th17 and high cytotoxicity of CD8 T
cells, in the peripheral blood of a patient suffering from a severe and
lethal form of COVID-19. The authors suggested that the important
immune response could account for, at least in part, the severe lung
immune injury in COVID-19 patients. Likewise, lymphopenia has been
suggested as the result of lung sequestration of hyperactivated T-cells.
In other words, inflammatory response and overaction of both T cells
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immune response in viral pneumonia could be a double-edged sword.
Although immunosuppressed SSc patients, particularly those with
ILD, could be potentially more susceptible to SARS-CoV2 infection with
severe clinical manifestations, the anti-inflammatory effects of im-
munosuppression could decrease the clinical expression of disease.
Besides specific anti-IL6 effects mediated by tocilizumab, both cyclo-
phosphamide and mycophenolate mofetil (MMF), the most commonly
used drugs for the treatment of patients with progressive SSc-ILD, act as
regulator of proliferation, survival and maturation of T-cells.
Furthermore, MMF inhibits interleukin −17 (IL-17) production with a
specific inhibition on Th17 cells [13]. Then, we can speculate that
suppression of pro-inflammatory cytokines and T-cell activities by
steroids and other immunosuppressive agents might be protective, even
in SSc patients. Broadly speaking, there is some evidence that the use of
anti-inflammatory agents, and namely of corticosteroids, may induce
some improvement in the acute phase of this and other viral infections
[17].
The patients with pre-existing cardiovascular disease appear to have
heightened vulnerability to develop COVID-19 and tend to have more
severe disease with worse clinical outcomes [18]. Cardiac involvement,
due to both primary myocardiopathy and secondary to pulmonary hy-
pertension, is common in SSc and associated with increased morbidity
and mortality [19]. At the moment we do not know the impact of pre-
existing scleroderma cardiac involvement on COVID-19 course.
Finally, it is highly desirable that future studies may be specifically
addressed to the clinical course and outcome of COVID-19 in SSc pa-
tients under chronic immunosuppressive therapies and with pre-ex-
isting heart and pulmonary involvement.
References
[1] Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus
disease 2019 outbreak in China. J Clin Med 2020;9(2). https://doi.org/10.3390/
jcm9020575. pii: E575.
[2] Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Latin
American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-
19). Clinical, laboratory and imaging features of COVID-19: a systematic review and
meta-analysis. Travel Med Infect Dis 2020:101623. in press https://doi.org/10.
1016/j.tmaid.2020.101623.
[3] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term
outcomes of 144 patients with SARS in the greater Toronto area. JAMA
2003;289(21):2801–9. https://doi.org/10.1001/jama.289.21.JOC30885.
[4] Chan JF, Lau SK, To KK, et al. Middle East respiratory syndrome coronavirus: an-
other zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev
2015;28(2):465–522. https://doi.org/10.1128/CMR.00102-14.
[5] Who Mers-Cov Research Group. State of Knowledge and data Gaps of Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLos Curr 2013;5.
https://doi.org/10.1371/currents.outbreaks.
0bf719e352e7478f8ad85fa30127ddb8. pii: ecurrents.outbreaks.
0bf719e352e7478f8ad85fa30127ddb8.
[6] Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19
infection and rheumatoid arthritis: faraway, so close!. Autoimmun Rev 2020
Mar;20:102523. https://doi.org/10.1016/j.autrev.2020.102523. [Epub ahead of
print].
[7] Marotto D, Sarzi-Puttini P. What is the role of rheumatologists in the era of COVID-
19? Autoimmun Rev 2020 Apr 3:102539. https://doi.org/10.1016/j.autrev.2020.
102539. [Epub ahead of print].
[8] Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course
of COVID-19 in a series of patients with chronic arthritis treated with im-
munosuppressive targeted therapies. Ann Rheum Dis 2020. https://doi.org/10.
1136/annrheumdis-2020-217424. pii: annrheumdis-2020-217424. [Epub ahead of
print].
[9] Mao R, Liang J, Shen J, Ghosh S, et al. Implications of COVID-19 for patients with
pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020 Mar 11. https://
doi.org/10.1016/S2468-1253(20)30076-5. pii: S2468–1253(20)30076-5. [Epub
ahead of print].
[10] Norsa L, Indriolo A, Sansotta N, Cosimo P, Greco S, D’Antiga L. Uneventful course in
IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology 2020.
https://doi.org/10.1053/j.gastro.2020.03.062. pii: S0016-5085(20)30445-5. [Epub
ahead of print].
[11] Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009 May
7;360(19):1989–2003. https://doi.org/10.1056/NEJMra0806188.
[12] Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated in-
terstitial lung disease. Lancet Respir Med 2020;8(3):304–20. https://doi.org/10.
1016/S2213-2600(19)30480-1.
[13] Roofeh D, Khanna D. Management of systemic sclerosis: the first five years. Curr
Opin Rheumatol 2020;32(3):228–37. https://doi.org/10.1097/BOR.
0000000000000711.
[14] Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic sclerosis
treated with tocilizumab for SSc-ILD. Ann Rheum Dis 2020. https://doi.org/10.
1136/annrheumdis-2020-217442. pii: annrheumdis-2020-217442. [Epub ahead of
print].
[15] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
2020. https://doi.org/10.1016/S0140-6736(20)30566-3. pii: S0140-6736(20)
30566-3. [Epub ahead of print].
[16] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–2. https://doi.
org/10.1016/S2213-2600(20)30076-X.
[17] Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs
and corticosteroids: should we be limiting their use in the clinical setting?
Ecancermedicalscience 2020 Mar 30;14:1023. https://doi.org/10.3332/ecancer.
2020.1023. [eCollection 2020].
[18] Stein R. COVID-19: risk groups, mechanistic insights, and challenges. Int J Clin
Pract 2020:e13512. https://doi.org/10.1111/ijcp.13512. [Epub ahead of print].
[19] Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and the heart. Rheum
Dis Clin North Am 2014;40(1):87–102. https://doi.org/10.1016/j.rdc.2013.10.007.
Nicoletta Del Papaa,⁎, Gianluca Sambatarob, Antonina Minnitia,
Francesca Pignataroa, Roberto Caporalia,c
aDepartment of Rheumatology, Gaetano Pini Hospital, Milan, Italy
b Regional Referral Center for Rare Lung Diseases, Department of Clinical
and Experimental Medicine, University of Catania, Italy
cUniversity of Milan, Dept. of Clinical Sciences and Community Health,
Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy
E-mail address: Nicoletta.DelPapa@asst-pini-cto.it (N. Del Papa).
⁎ Corresponding author.
Autoimmunity Reviews 19 (2020) 102558
2
